7.95亿美元被收购!Sage另觅他主,Biogen“抄底”失败

药时代
Yesterday

2025年6月16日,Supernus Pharmaceuticals和Sage Therapeutics宣布达成最终协议,Supernus将以每股8.50美元的现金支付(总计约5.61亿美元)收购Sage的所有已发行股份。此外,Sage股东还将获得一份不可交易的或有价值权(CVR),该权利在达到某些特定的销售和商业里程碑时,每股可额外支付高达3.50美元(总计约2.34亿美元)。因此本次交易的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10